When you need surgery for early-stage lung cancer, you want the approach that gives you the best shot at a long life. For years, doctors have known that a less invasive surgery called VATS (video-assisted thoracoscopic surgery) typically means less pain and a faster recovery than traditional open surgery. But a big question remained: does it also help people live longer? A new analysis combining data from three major studies finally provides an answer. The analysis looked at nearly 1,200 patients. It found that people who had the VATS procedure had a 21% lower risk of dying from any cause compared to those who had open surgery. When it came to cancer coming back, there was no real difference between the two groups—both approaches were equally effective at keeping the cancer at bay. This is important because it shows that the less invasive surgery isn't just about a better recovery; it's also linked to better long-term survival. The researchers conclude that when it's technically possible, VATS should be the preferred choice for removing early-stage lung cancer.
Does a less invasive lung cancer surgery help people live longer? New analysis says yes
Photo by Navy Medicine / Unsplash
What this means for you:
For early-stage lung cancer, less invasive VATS surgery is linked to living longer than open surgery. More on Non-Small Cell Lung Cancer
RNK08954 shows unconfirmed responses in KRASG12D-mutant NSCLC and PDAC in Phase Ia trial New drug shows promise for KRASG12D lung and pancreatic cancers
· May 1, 2026
Subcutaneous tislelizumab shows comparable trough concentrations to intravenous dosing in treatment-naive advanced non-small cell lung cancer patients Phase I trial shows subcutaneous tislelizumab reaches high drug levels in lung cancer patients
· May 1, 2026
Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression Five-year follow-up shows pembrolizumab extends life for Chinese lung cancer patients with high PD-L1
· May 1, 2026
High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors High Mutation Counts May Predict Better Cancer Survival Outcomes
· May 1, 2026